2015 Press Releases

Keyword Search
 
DateTitle  
10-Dec-2015ERYTECH Wins the European Small and Mid-Cap Award in the Most Innovative Newcomer Category
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other malignancies with unmet medical needs, announced today that it received yesterday evening the “European Small and Mid-Cap” award in the “Most Innovative Newcomer” category by the Federation of European Stock Exchanges. The Federation of European Securiti... 
Download PDFPrinter Friendly Version
08-Dec-2015ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) , the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other malignancies with unmet medical needs, announces that investigators presented additional results from the pivotal Phase 2/3 clinical trial with GRASPA that add to the body of data supporting the potential benefit of GRASPA in combination with chemotherapy in the treatment of Acute Lymphoblastic Leukemia (ALL). These results, which w... 
Download PDFPrinter Friendly Version
07-Dec-2015ERYTECH raises approximately €25.4 million in a private placement
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs (the "Company"), today announcesthe closing of a private placement of 940,000 ordinary shares to qualified investors in the United States and Europe for a total amount of approximately €25.4 million. The Company intends to use the proceeds from the private placemen... 
Download PDFPrinter Friendly Version
18-Nov-2015ERYTECH wins Deloitte Technology Fast 50 “Promising Biotech Award” for France’s Grand Rhone-Alpes Region
ERYTECH Pharma (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other malignancies with unmet medical needs, announced today that it received Deloitte Technology Fast 50 award in the “Promising Biotech” category for France’s Grand Rhone-Alpes region. Created in 2001, the Deloitte Technology Fast 50 is a prominent award program for growing technology companies... 
Download PDFPrinter Friendly Version
05-Nov-2015ERYTECH Announces Data Presentations at the American Society of Hematology 57th Annual Meeting
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other malignancies with unmet medical needs, announces the upcoming presentation of three abstracts at the American Society of Hematology (ASH) Annual Meeting taking place in Orlando, Florida, USA from December 5-8, 2015. The poster presentations include: Updated Clinical Activity... 
Download PDFPrinter Friendly Version
03-Nov-2015ERYTECH Reports Financial Highlights for Q3 2015
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, reports cash balance and revenues for the third quarter of 2015. ERYTECH ended the third quarter of 2015 with a total net cash position, including short term treasury investments, of € 28.2 million, compared to total net cash position of € 31.0 million at the end of the secon... 
Download PDFPrinter Friendly Version
20-Oct-2015ERYTECH announces publication of two articles describing clinical results with ERY-ASP/GRASPA
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the publication of two peer-reviewed manuscripts describing clinical results obtained with ERY-ASP/GRASPA®. The first article, published in the September 2015 issue of the American Journal of Hematology, entitled ”A Phase 2 study of L-asparaginase encapsulated... 
Download PDFPrinter Friendly Version
28-Sep-2015ERYTECH Provides Business Update and Financial Results for the First Half of 2015
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, provides a business update and reports its financial results for the six-month period ending June 30, 2015. Business Highlights Centralized Marketing Authorization Application (MAA) for GRASPA submitted to the European Medicines Agency (EMA) for the treatment of patients with ALL ... 
Download PDFPrinter Friendly Version
14-Sep-2015ERYTECH submits EMA Marketing Authorization Application for GRASPA to treat acute lymphoblastic leukemia
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces today the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ERY-ASP (Invented Name: GRASPA®) for the treatment of patients with acute lymphoblastic leukemia (ALL). The MAA for GRAS... 
Download PDFPrinter Friendly Version
01-Sep-2015ERYTECH appoints Eric Soyer as Chief Financial and Chief Operating Officer
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the appointment of Eric Soyer as Chief Financial and Chief Operating Officer (CFO/COO). Mr. Soyer brings more than 20 years of experience in executive leadership positions with responsibility for financial and operational functions with establ... 
Download PDFPrinter Friendly Version
28-Jul-2015ERYTECH announces plans to conduct registered initial public offering in the United States
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that the Company plans to conduct a registered initial public offering in the United States. This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. As required by Rule 135, this pre... 
Download PDFPrinter Friendly Version
20-Jul-2015ERYTECH announces positive safety review for ERY-ASP in its Phase 2 study in pancreatic cancer
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces a positive DSMB safety review following the treatment of the first twenty-four patients with ERY-ASP in its Phase 2 study in pancreatic cancer. The ERY-ASP pancreatic cancer Phase 2 study is a multicenter, randomized trial in ... 
Download PDFPrinter Friendly Version
15-Jul-2015ERYTECH appoints Dr. Iman El-Hariry as Chief Medical Officer
ERYTECH Inc., the US affiliate of ERYTECH Pharma (Euronext Paris: ERYP) (Paris:ERYP) (ADR:EYRYY),the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs. Iman El-Hariry, M.D., Ph.D., is an oncologist with more than 15 years of global produ... 
Download PDFPrinter Friendly Version
08-Jul-2015ERYTECH reports financial highlights for Q2 2015
ERYTECH Pharma (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, reports cash balance and revenues for the second quarter of 2015. ERYTECH ended the second quarter of 2015 with a cash balance of € 30.6 million. The cash position was € 34.0 million at the end of the first quarter of 2015 and € 37.0 million at the end of 2014. Th... 
Download PDFPrinter Friendly Version
22-Jun-2015ERYTECH announces two positive DSMB reviews
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces positive safety reviews after the completion of the first cohort in the company’s US Phase I study with ERY-ASP in Acute Lymphoblastic Leukemia (ALL), and following the treatment of the first three patients with ERY-ASP in ... 
Download PDFPrinter Friendly Version
02-Jun-2015ERYTECH Announces Presentation and Webcast at the Jefferies 2015 Healthcare Conference
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces that Gil Beyen, Chairman & CEO of the company, will present a company overview at the Jefferies 2015 HealthCare Conference in New York on June 4 at 9:00 am Eastern Time. A webcast of the presentation will be available under We... 
Download PDFPrinter Friendly Version
01-Jun-2015ERYTECH reported full GRASPA® Phase III results in ALL and provided update on AML Phase IIb at ASCO
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, reported complete Phase III results of its pivotal program with GRASPA® in Acute Lymphoblastic Leukemia (ALL) and presented the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) at the 51st Annual Meeting of the America... 
Download PDFPrinter Friendly Version
20-May-2015ERYTECH announces oral presentations of GRASPA® Phase III results at ASCO and EHA annual meetings
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the data related to GRASPA® Phase 3 pivotal program in Acute Lymphoblastic Leukemia (ALL) will be the subject of oral presentations at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 - Jun... 
Download PDFPrinter Friendly Version
05-May-2015ERYTECH announces positive DSMB annual review of its Expanded Access Program in ALL
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s Expanded Access Program (EAP) in Acute Lymphoblastic Leukemia (ALL) and recommended continuation of the prog... 
Download PDFPrinter Friendly Version
05-May-2015ERYTECH reports financial highlights for Q1 2015
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, reports cash balance and revenues for the first quarter of 2015. ERYTECH ended the first quarter of 2015 with a cash balance of € 34.0 million. The cash position was € 37.0 million at the end of 2014. The net use of cash for operational an... 
Download PDFPrinter Friendly Version
28-Apr-2015ERYTECH receives the EnterNext Tech 40 Label
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), a French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, has received the EnterNext Tech 40 Label and announces its inclusion in the Tech 40 index. Wanting to give more prominence to outstanding listed Tech companies, every year EnterNext grants its Tech 40 label to 40 out of over 320 small and ... 
Download PDFPrinter Friendly Version
21-Apr-2015ERYTECH strengthens its intellectual property position in the US
ERYTECH (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the strengthening of its intellectual property portfolio in the United States with the granting of a new patent and the further extension of the patent term of its core process patent. The patent entitled “Medicament for the Treatment of Cancer of the Pancreas”... 
Download PDFPrinter Friendly Version
30-Mar-2015ERYTECH provides business update and financial results for the full year 2014
ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, provides a business update and reports its financial results for the period ending December 31, 2014. Business Highlights Positive Phase III results from pivotal study with GRASPA® in Acute Lymphoblastic Leukemia (ALL) Positive DS... 
Download PDFPrinter Friendly Version
26-Mar-2015ERYTECH appoints new independent board member
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces it has coopted Luc Dochez as new independent board member and will propose his appointment at the upcoming general assembly in June. Luc Dochez, has served as Chief Business Officer and Senior Vice-President of Business Developm... 
Download PDFPrinter Friendly Version
24-Mar-2015ERYTECH announces three data presentations at the 2015 AACR Annual Meeting
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the upcoming presentation of three abstracts, at the American Association for Cancer Research (AACR) taking place in Philadelphia, PA, USA from 18 to 22 April 2015. Details for the three posters are as follows: A phase... 
Download PDFPrinter Friendly Version
10-Feb-2015ERYTECH reports financial highlights for Q4 2014 and updates on upcoming milestones
ERYTECH Pharma (Paris:ERYP) (Euronext Paris: ERYP & OTC US: EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, reports revenues and cash balance for the fourth quarter of 2014 and provides an update on upcoming milestones. ERYTECH ended the year 2014 with a cash balance of € 37.0 million. This compares to a cash position of € 15.1 million at the end of 2013 an... 
Download PDFPrinter Friendly Version
12-Jan-2015ERYTECH announces ADR Level 1 listing in the US
ERYTECH (Paris:ERYP)(Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company's US investor base. An ADR Level 1 is a negotiable US security representing ownership of publicl... 
Download PDFPrinter Friendly Version
08-Jan-2015ERYTECH announces management change
ERYTECH (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests. Pierre-Olivier Goineau was one of the co-founders of the company and has been instrumental in advancing the business both in terms of its operational and fin... 
Download PDFPrinter Friendly Version
Top